• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SOFRADIM PRODUCTION SAS MESH SOFRADIM - UGYTEX¿; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR PELVIC ORGAN PROLAPSE, TRANSVAGIN

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SOFRADIM PRODUCTION SAS MESH SOFRADIM - UGYTEX¿; MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR PELVIC ORGAN PROLAPSE, TRANSVAGIN Back to Search Results
Model Number UGYKP
Device Problems Material Erosion (1214); Adverse Event Without Identified Device or Use Problem (2993); Patient Device Interaction Problem (4001)
Patient Problems Erosion (1750); Cyst(s) (1800); Micturition Urgency (1871); Incontinence (1928); Inflammation (1932); Pain (1994); Urinary Tract Infection (2120); Hernia (2240); Urinary Frequency (2275); Injury (2348); Disability (2371); Fungal Infection (2419); Prolapse (2475); Abdominal Distention (2601); Dysuria (2684); Fibrosis (3167); No Code Available (3191); Constipation (3274)
Event Type  Injury  
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of urogynecological.It was reported that after implant, the patient experienced uterine prolapse, pelvic relaxation, pelvic pain, stress urinary incontinence and menometrorrhagia.Treatment includes revision.
 
Manufacturer Narrative
If information is provided in the future, a supplemental report will be issued.
 
Event Description
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of stress urinary in continence.The patient has experienced injury, pain, disability, impairment, uterine prolapse, pelvic relaxation, pelvic pain, menometrorrhagia, recurrent urinary tract infections, mesh erosion, umbilical hernia, having lost her g-spot, decreased libido, severe dyspareunia, vaginal dryness, severe yeast infection, hypoestrogenic, hormone pellet therapy, sensation of pelvic floor falling, sensation of something poking her, partner feeling something, mesh exposure with excision, overactive bladder, recurrent stress urinary incontinence, frequency, mixed incontinence, recurrent pelvic prolapse, sexual dysfunction, urgency, recurrent rectocele, sensation of a bulge in the posterior aspect of the rectum, and ventral hernia.Post-operative patient treatment included nonsurgical and surgical interventions.
 
Manufacturer Narrative
Additional information: a4, b5, b6, b7, d2, d11, e3, g4, h6(added patient codes, added device codes, and removed code a040503).Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
The patient¿s attorney alleged a deficiency against the device.The product was used for therapeutic treatment of stress urinary in continence.The patient has experienced injury, pain, disability, impairment, uterine prolapse, pelvic relaxation, pelvic pain, menometrorrhagia, recurrent urinary tract infections, mesh erosion, umbilical hernia, having lost her g-spot, decreased libido, severe dyspareunia, vaginal dryness, severe yeast infection, hypoestrogenic, sensation of pelvic floor falling, sensation of something poking her, partner feeling something, mesh exposure with excision, overactive bladder, recurrent stress urinary incontinence, frequency, mixed incontinence, recurrent pelvic prolapse, sexual dysfunction, urgency, recurrent rectocele, sensation of a bulge in the posterior aspect of the rectum, small uterine fibroid, adenomyosis, endocervicitis, hemorrhagic corpus luteum cyst, left paratubal cystic change, inflammation, fibrous tissue, burning with urination, constipation, right ureteral orifice was somewhat laterally displaced, and ventral hernia.Post-operative patient treatment included nonsurgical and surgical interventions, laparoscopic assisted vaginal hysterectomy, bilateral salpingo-oophorectomy, hormone pellet therapy, and implantation of new xenform mesh.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MESH SOFRADIM - UGYTEX¿
Type of Device
MESH, SURGICAL, SYNTHETIC, UROGYNECOLOGIC, FOR PELVIC ORGAN PROLAPSE, TRANSVAGIN
Manufacturer (Section D)
SOFRADIM PRODUCTION SAS
116 avenue du formans
trevoux 01600
FR  01600
MDR Report Key7838931
MDR Text Key118954193
Report Number9615742-2018-01967
Device Sequence Number1
Product Code OTP
Combination Product (y/n)N
PMA/PMN Number
K051503
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,other
Type of Report Initial,Followup,Followup
Report Date 03/27/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/31/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/31/2011
Device Model NumberUGYKP
Device Catalogue NumberUGYKP
Device Lot NumberZGA00037
Was Device Available for Evaluation? No
Date Manufacturer Received03/09/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
URETEXSUP(LOT#: SGA00160), UGYKA(LOT#: ZGA00038)
Patient Outcome(s) Other; Required Intervention;
Patient Age50 YR
Patient Weight66
-
-